Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Context Therapeutics Inc.NASDAQ: CNTX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $36.11K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $40.17K.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $36.11K or moves back toward the trailing-twelve-month quarterly average of $10.04K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36.11K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$40.17K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
CNTX Competitors
Cost of Revenue for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
IMAImageneBio IncLTM Mar 2026$780K USD-95.0%-74.8%—
CLNNClene Inc.LTM Mar 2026$378K USD+410.8%+18.3%282.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.17K USD———
OVIDOvid Therapeutics Inc.LTM Mar 2026$35K USD——0.5%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$31K USD-98.5%——
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
WHWKWhitehawk Therapeutics IncLTM Mar 2026$5K USD-100.0%-71.8%—
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding CNTX) —-36.2%-26.8%106.0%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.